goserelin + ibandronate

Goserelin + ibandronate is a combination of two pharmaceutical agents used primarily in the management of hormone-sensitive cancers and cancer treatment-induced bone loss. Goserelin is a synthetic analog of luteinizing hormone-releasing hormone (LHRH) that acts as a gonadotropin-releasing hormone agonist, leading to suppression of sex hormones such as testosterone and estradiol. This mechanism is utilized in the treatment of prostate cancer, breast cancer, endometriosis, and other conditions where hormonal suppression is beneficial[1][3]. Ibandronate is a third-generation nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption and is used to treat or prevent osteoporosis, particularly in postmenopausal women[2][4]. In oncology settings, bisphosphonates like ibandronate are also employed to manage bone metastases and prevent skeletal-related events by reducing tumor-stimulated osteolysis[5][7]. The combination may be considered for patients with breast or prostate cancer who are at risk for both disease progression due to hormonal stimulation and treatment-induced bone loss.

Brand names

Zoladex (goserelin)Boniva (ibandronate)Bondronat (ibandronate)Bonviva (ibandronate)Iasibon (ibandronate)Ibandronic Acid Teva (ibandronate)

Other names

GoserelinaDecapeptide Iácido ibandronicóIbandronic acid